Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

Gurumurthy, Prema ; Ramachandran, Geetha ; Hemanth Kumar, A. K. ; Rajasekaran, S. ; Padmapriyadarsini, C. ; Swaminathan, Soumya ; Bhagavathy, S. ; Venkatesan, P. ; Sekar, L. ; Mahilmaran, A. ; Ravichandran, N. ; Paramesh, P. (2004) Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease Antimicrobial Agents and Chemotherapy, 48 (11). pp. 4473-4475. ISSN 0066-4804

Full text not available from this repository.

Official URL: http://aac.asm.org/content/48/11/4473

Related URL: http://dx.doi.org/10.1128/AAC.48.11.4473-4475.2004

Abstract

We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.

Item Type:Article
Source:Copyright of this article belongs to American Society for Microbiology.
ID Code:109871
Deposited On:01 Sep 2017 09:02
Last Modified:01 Sep 2017 09:02

Repository Staff Only: item control page